Patents by Inventor Sung Won An

Sung Won An has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same
    Patent number: 10722585
    Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 28, 2020
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Sang Phil Yoon, Ki Seong Ko, Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, So Hyun Park, Sung Bum Jung, Sung Won An, Min Hyo Ki
  • Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
    Patent number: 9526787
    Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: December 27, 2016
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki
  • SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH ANALOGUES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20150297726
    Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
    Type: Application
    Filed: December 27, 2013
    Publication date: October 22, 2015
    Inventors: Sang Phil Yoon, Ki Seong Ko, Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, So Hyun Park, Sung Bum Jung, Sung Won An, Min Hyo Ki
  • SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF CATIONIC PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20150265535
    Abstract: Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.
    Type: Application
    Filed: December 27, 2013
    Publication date: September 24, 2015
    Inventors: Ha Na Yu, Hye Jung Baik, Won Kyu Yang, Jin Young Ko, Sung Bum Jung, Sung Won An, Min Hyo Ki
  • Sustained-Release Lipid Pre-Concentrate of Pharmacologically Active Substance And Pharmaceutical Composition Comprising The Same
    Publication number: 20140206616
    Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.
    Type: Application
    Filed: August 28, 2012
    Publication date: July 24, 2014
    Applicant: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki